Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mitchell S Anscher

Showing results (1-10 of 108) with videos related to

Pageof 11
Sort By:
JAMA|March 18, 2004
Salvage radiotherapy for recurrent prostate cancer: the earlier the betterMitchell S Anscher
Urology|August 28, 2019
EDITORIAL COMMENTMitchell S Anscher
International Journal of Radiation Oncology, Biology, Physics|October 20, 2012
Self-referral in radiation oncology: has caveat emptor replaced primum non nocere?Mitchell S Anscher
The Oncologist|April 24, 2010
Targeting the TGF-beta1 pathway to prevent normal tissue injury after cancer therapyMitchell S Anscher
JAMA|July 28, 2005
PSA kinetics and risk of death from prostate cancer: in search of the Holy Grail of surrogate end pointsMitchell S Anscher
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2005
The irreversibility of radiation-induced fibrosis: fact or folklore?Mitchell S Anscher
Seminars in Oncology|July 15, 2005
Mechanisms and potential targets for prevention and treatment of normal tissue injury after radiation therapyMitchell S Anscher, Zeljko Vujaskovic
Nature Reviews. Urology|July 17, 2013
Prostate cancer: should men with metastases undergo radical prostatectomy?Drew Moghanaki, Mitchell S Anscher
Brachytherapy|April 29, 2006
Medical malpractice in the age of technology: how specialty societies can make a differenceMitchell S Anscher, Barbara M Anscher
International Journal of Radiation Oncology, Biology, Physics|March 9, 2005
In regard to De Jaeger et al.: significance of plasma transforming growth factor-beta levels in radiotherapy for non-small-cell lung cancer (INT J RADIAT ONCOL BIOL PHYS 2004;58:1378-1387)Mitchell S Anscher, Feng-Ming Kong
Pageof 11

Showing results (1-10 of 108) with videos related to

Sort By:
Pageof 11
JAMA|March 18, 2004
Salvage radiotherapy for recurrent prostate cancer: the earlier the betterMitchell S Anscher
Urology|August 28, 2019
EDITORIAL COMMENTMitchell S Anscher
International Journal of Radiation Oncology, Biology, Physics|October 20, 2012
Self-referral in radiation oncology: has caveat emptor replaced primum non nocere?Mitchell S Anscher
The Oncologist|April 24, 2010
Targeting the TGF-beta1 pathway to prevent normal tissue injury after cancer therapyMitchell S Anscher
JAMA|July 28, 2005
PSA kinetics and risk of death from prostate cancer: in search of the Holy Grail of surrogate end pointsMitchell S Anscher
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2005
The irreversibility of radiation-induced fibrosis: fact or folklore?Mitchell S Anscher
Seminars in Oncology|July 15, 2005
Mechanisms and potential targets for prevention and treatment of normal tissue injury after radiation therapyMitchell S Anscher, Zeljko Vujaskovic
Nature Reviews. Urology|July 17, 2013
Prostate cancer: should men with metastases undergo radical prostatectomy?Drew Moghanaki, Mitchell S Anscher
Brachytherapy|April 29, 2006
Medical malpractice in the age of technology: how specialty societies can make a differenceMitchell S Anscher, Barbara M Anscher
International Journal of Radiation Oncology, Biology, Physics|March 9, 2005
In regard to De Jaeger et al.: significance of plasma transforming growth factor-beta levels in radiotherapy for non-small-cell lung cancer (INT J RADIAT ONCOL BIOL PHYS 2004;58:1378-1387)Mitchell S Anscher, Feng-Ming Kong
Pageof 11